Application of IMO-2055 and additional TLR9 agonists for cancer treatment

In December 2007, Idera entered into an exclusive, worldwide licensing and collaboration agreement with Merck KGaA, of Darmstadt, Germany, for the research, development, and commercialization of Idera's TLR9 agonists for the treatment of cancer. Under the agreement, Idera agreed to exclusively license the applications of its lead TLR9 agonists, IMO-2055 and IMO-2125, for treating cancer, excluding the use of these compounds with cancer vaccines. In addition, Merck KGaA and Idera have agreed to engage in a research collaboration to identify a specified number of novel, follow-on TLR9 agonists, which will be derived using Idera’s chemistry-based approach and for which Merck KGaA will have the exclusive right to use for treating cancer, excluding the use of these compounds with cancer vaccines.

Please click here for more information on this collaboration